Skip to main content

Table 5 Ovarian cancer member characteristics by stage, diagnosed 2016–2020 (N = 723)

From: Increased healthcare costs by later stage cancer diagnosis

Stage

I

II

III

IV

n (%)a, b

247 (34.2%)

79 (10.9%)

270 (37.3%)

127 (17.6%)

Age, mean (SD), yearsb

53.5 (14.6)

58.5 (12.1)

59.6 (13.3)

61.5 (11.3)

Female Gender, n (%)b

247 (100.0%)

79 (100.0%)

270 (100.0%)

127 (100.0%)

Insurance Type, n (%)a, b

 Commercial

153 (61.9%)

46 (58.2%)

131 (48.5%)

71 (55.9%)

 Medicaid

15 (6.1%)

8 (10.1%)

10 (3.7%)

4 (3.2%)

 Medicare Advantage

57 (23.1%)

24 (30.4%)

99 (36.7%)

46 (36.2%)

 Multiplec

0 (0.0%)

0 (0.0%)

2 (0.7%)

0 (0.0%)

 Unknown

22 (8.9%)

1 (1.3%)

28 (10.4%)

6 (4.7%)

Geographic Region, n (%)a, b

 Midwest

105 (42.5%)

25 (31.7%)

115 (42.6%)

45 (35.4%)

 Northeast

92 (37.3%)

27 (34.2%)

78 (28.9%)

34 (26.8%)

 South

26 (10.5%)

15 (19.0%)

47 (17.4%)

23 (18.1%)

 West

18 (7.3%)

8 (10.1%)

26 (9.6%)

17 (13.4%)

 Unknown

6 (2.4%)

4 (5.1%)

4 (1.5%)

8 (6.3%)

CCI, mean (SD)d

0.7 (1.1)

0.9 (1.4)

1.0 (1.5)

1.2 (1.6)

CCI, n (%)a, d

 0

73 (64.0%)

20 (57.1%)

68 (57.6%)

32 (44.4%)

 1

23 (20.2%)

8 (22.9%)

21 (17.8%)

16 (22.2%)

 2

10 (8.8%)

4 (11.4%)

14 (11.9%)

14 (19.4%)

  ≥ 3

8 (7.0%)

3 (8.6%)

15 (12.7%)

10 (13.9%)

  1. Charlson Comorbidity Index; SD Standard deviation
  2. a Percentages may not total to 100% due to rounding
  3. b Demographics were calculated at the time of cancer diagnosis
  4. c Individuals had insurance eligibility from multiple types during this period
  5. d CCI was calculated among subjects with 6 months of continuous insurance eligibility prior to their cancer diagnosis